Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22576485 | 0.81 | SORT1 (0.39) | SORT1NR2F2RAB9ANAMPTNOS3 | |
| SCHEMBL171770 | 0.80 | SMN1; SMN2 (0.50) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL22576461 | 0.79 | SORT1 (0.38) | SORT1NR2F2RAB9ANAMPTNOS3 | |
| SCHEMBL11991398 | 0.79 | SORT1 (0.38) | SORT1NR2F2RAB9ANAMPTNOS3 | |
| SCHEMBL7146824 | 0.78 | NR2F2 (0.40) | SORT1NR2F2RAB9ANAMPTNOS3 | |
| SCHEMBL24452449 | 0.77 | MAPT (0.38) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL22629496 | 0.77 | MAPT (0.38) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL22628891 | 0.77 | MAPT (0.35) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL17788496 | 0.76 | MAPT (0.40) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL21169150 | 0.76 | SORT1 (0.36) | SMN1; SMN2SORT1NR2F2RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2021076805-A1 | MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | Moderna TX, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021026358-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020227510-A1 | POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-23 | — | — | US | disclosed |
| US-9868693-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867888-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | MAPT 718/4885CYP2C9 1927/4885CYP2C19 1593/4885 |
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | MAPT 2478/4885CYP2C9 4860/4885CYP2C19 4882/4885 |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | MAPT 2478/4885CYP2C9 4860/4885CYP2C19 4882/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | MAPT 3414/4885CYP2C9 1794/4885CYP2C19 855/4885 |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | MAPT 4558/4885CYP2C9 3163/4885CYP2C19 2819/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | MAPT 3072/4885CYP2C9 1741/4885CYP2C19 3172/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | MAPT 4179/4885CYP2C9 683/4885CYP2C19 881/4885 |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | MAPT 3549/4885CYP2C9 3255/4885CYP2C19 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.